ERIN LEE: Open Payments
NPI 1760028294 · MADISON, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$747 in 38 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $89 · 2025 $747
Food & beverage: $747
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 6 | $132 |
| Novo Nordisk Inc | 6 | $108 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $102 |
| Merck Sharp & Dohme LLC | 4 | $79 |
| AstraZeneca Pharmaceuticals LP | 3 | $56 |
| Amgen Inc. | 3 | $52 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| PFIZER INC. | 2 | $39 |
| SANOFI PASTEUR INC. | 1 | $34 |
Products named: MOUNJARO, Kerendia, XIFAXAN, LAGEVRIO, GEMTESA, PREVNAR 20, Rybelsus, BREZTRI.
Industry payments across AL — which companies pay providers there.
